MedTrace Logo

Study of DTRI-031 in Healthy Volunteers

NCT05005520 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2022-07-19

No results posted yet for this study

Summary

A randomized, double-blind, single center, placebo-controlled phase 1 study in healthy volunteers to assess safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single intravenous (iv) injection of DTRI-031

Conditions

  • Healthy Volunteers
  • Pharmacokinetics
  • Pharmacodynamics

Interventions

DRUG

DTRI-031

Investigational drug

DRUG

Placebo

Matching placebo to DTRI-031

Sponsors & Collaborators

  • Basking Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2022-04-19
Completion
2022-04-19
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005520 on ClinicalTrials.gov